ABSTRACT
Aims: The aim of the study is to compare the effect of Mometasone Fuorate and Levocetrizine in alleviating the symptom triad of Rhinorrhoea, Nasal obstruction and Sneezing in patients of Allergic Rhinitis. Study Design: Prospective cohort study. Place and Duration of Study: Department of Otolaryngology, Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sevagram, between 1st April 2012 to 31st March 2014. Methodology: In this study 50 patients were assessed. The diagnosis was made on the basis of 1) Careful detailed history, 2) Clinical examinations, 3) ARIA Classification was used to classify the patients. Patients received, Group A: Mometasone furoate nasal spray 50 µg in each nostril twice daily for the first 7 days followed by once daily upto 8 weeks, Group B: Levocetrizine 5 mg in the night for 8 weeks. In followup period of 12 weeks Patients receivedGroup A: Mometasone furoate nasal spray 50 µg in each nostril once daily for 12 weeks. Group B: Levocetrizine 5 mg in the night for 12 weeks. Results: In patients with Intermittent Symptoms, 76% of the participants in the group A were found to be relieved of the nasal discharge as compared to 24% in the group B. This difference was found to be statistically significant (P = .0007). 83% of the participants in the group A were found to be relieved of the nasal obstruction as compared to 17% in the group B. This difference was found to be statistically significant (P = .0022). 61.5% of the participants in the group A were found to be relieved of the sneezing as compared to 48.5% in the group B. This difference was not found to be statistically significant (P=0.8017). In patients with Persistent Symptoms, 84.6% of the participants in the group A were found to be relieved of the nasal discharge as compared to 15.4% in the group B. This difference was found to be statistically significant (P = .0124). 100% of the participants in the group A were found to be relieved of the nasal obstruction as compared to 0% in the group B. This difference was found to be statistically significant (P = .0006). 75% of the participants in the group A were found to be relieved of the sneezing as compared to 25% in the group B. This difference was not found to be statistically significant (P = .5647). Conclusion: In this study we conclude that both Mometasone Fuorate and Levocetrizine are potent drugs for the management of allergic rhinitis but because of the local action and a high lipophilicity, longer retainability and induction of apoptosis of eosinophills in the nasal mucosa, patients taking Mometasone Fuorate as medication appreciate better relief in symptoms as compared to Levocetrizine.